150 related articles for article (PubMed ID: 10960842)
61. Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma.
Soylu H; Acar N; Ozbey O; Unal B; Koksal IT; Bassorgun I; Ciftcioglu A; Ustunel I
Pathol Oncol Res; 2016 Jan; 22(1):87-94. PubMed ID: 26341090
[TBL] [Abstract][Full Text] [Related]
62. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
63. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
Stone NN; Stock RG; Unger P
Mol Urol; 2000; 4(3):163-8;discussion 169-70. PubMed ID: 11062370
[TBL] [Abstract][Full Text] [Related]
64. Needle biopsy findings in prostatic adenocarcinoma: experience at a tertiary care center in a developing country.
Ahmad Z; Arshad H
Ann Diagn Pathol; 2013 Jun; 17(3):235-8. PubMed ID: 23199761
[TBL] [Abstract][Full Text] [Related]
65. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
66. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
67. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
Bostwick DG
Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
[TBL] [Abstract][Full Text] [Related]
68. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
69. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED
Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911
[TBL] [Abstract][Full Text] [Related]
70. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
71. [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
Fukuda M; Takashima H; Fuse H; Hirano S
Hinyokika Kiyo; 2002 Aug; 48(8):499-502. PubMed ID: 12243078
[TBL] [Abstract][Full Text] [Related]
72. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
73. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
74. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
75. Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.
Barbisan F; Mazzucchelli R; Santinelli A; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Histopathology; 2010 Oct; 57(4):572-9. PubMed ID: 20955382
[TBL] [Abstract][Full Text] [Related]
76. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Marchal C; Redondo M; Padilla M; Caballero J; Rodrigo I; García J; Quian J; Boswick DG
Histol Histopathol; 2004 Jul; 19(3):715-8. PubMed ID: 15168332
[TBL] [Abstract][Full Text] [Related]
77. Lymphatic vessel density in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer assessed in whole-mount sections.
Longatto-Filho A; Malheiro LF; Milanezi F; Pinheiro C; Baltazar F; Schmitt FC; Montironi R
Anal Quant Cytol Histol; 2009 Oct; 31(5):269-75. PubMed ID: 20701093
[TBL] [Abstract][Full Text] [Related]
78. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.
Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI
Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583
[TBL] [Abstract][Full Text] [Related]
79. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
80. Positive predictive value of high-grade prostatic intraepithelial neoplasia in initial core needle biopsies of prostate adenocarcinoma--a study with complete sampling of hemi-prostates with corresponding negative biopsy findings.
Delatour NL; Mai KT
Urology; 2008 Sep; 72(3):623-7. PubMed ID: 18279923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]